// App-Quantinova.ai

P180 : Minimal disease activity response patterns in bio-naïve patients with psoriatic arthritis treated with guselkumab: a machine learning analysis

Researchers

Presenter

  • ALEN ZABOTTI

Principal Investigators

  • Sarah Ohrndorf

  • William Tillett

  • Marlies Neuhold

  • Michel Van Speybroeck

  • Elke Theander

  • Christine Contré

  • Mohamed Sharaf

  • May Shawi

  • Michelle Perate

  • Alexa Kollmeier

  • Pascal Richette

Medical Centers

  • Janssen, Scientific Affairs, LLC, Issy-les-Moulineaux, France

  • Data Science, Janssen Pharmaceutica N.V., Beerse, Belgium

  • Rheumatology Department Lariboisière Hospital, Paris University, Paris, France

  • Rheumatology, Janssen-Cilag AB, Solna, Sweden

  • Department of Medical and Biological Sciences, Clinic of Rheumatology, Udine University, Udine, Italy

  • Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany

  • Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom

Locations

  • France

  • Italy

  • Belgium

  • United States

  • Germany

  • Switzerland

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved